|
|
1.
|
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. MedStar authors:
- Kurian, Shweta
- Mohebtash, Mahsa
- Ottaviano, Yvonne
- Rao, Suman
- Swain, Sandra M
Year: 2022
Citation: - Breast Cancer Research & Treatment. 196(3):571-581, 2022 Dec.
Institution: - MedStar Franklin Square Medical Center
Department:
- Associate Dean for Research Development
- Hematology/Oncology
- MedStar Health
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Randomized Controlled Trial
All authors: - Dilawari A, Graham D, Isaacs C, Kurian S, Lynce F, Mainor C, McNamara D, Mohebtash M, Ottaviano Y, Pohlmann PR, Rao S, Swain SM, Swanson N, Tan M, Warren R, Wu T
|
|
|
2.
|
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. MedStar authors:
Citation: - Lancet Oncology. 16(8):957-66, 2015 Aug.
Institution: - MedStar Washington Hospital Center
Department: - Surgery/Colorectal Surgery
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, N.I.H., Extramural
All authors: - Avila K, Cataldo PA, Chow OS, Coutsoftides T, Dietz DW, Fichera A, Garcia-Aguilar J, Herzig DO, Hunt SR, Kumar AS, Marcet JE, Oommen S, Patil S, Polite BN, Smith DD, Stamos MJ, Ternent CA, Timing of Rectal Cancer Response to Chemoradiation Consortium, Varma MG
|
